{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:03:21Z","timestamp":1791198201953,"version":"4.1.0"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>\n                    Proteins are a vital class of biomolecules. They play essential roles in biological processes, including building cellular structures, forming cellular channels and receptors, catalyzing biological reactions, transporting molecules, and contributing to immune defense mechanisms. Advances in protein engineering have enabled the genetic modification of naturally occurring proteins, using recombinant deoxyribonucleic acid (DNA) technology, leading to the development of therapeutic proteins with enhanced specificity, stability, and clinical performance. Despite the rapid growth of engineered biologics, a comprehensive understanding of how these innovations intersect with precision medicine remains limited. This review addresses this gap by summarizing the major contemporary approaches used in therapeutic protein engineering, including directed evolution, rational design, and\n                    <jats:italic>de novo<\/jats:italic>\n                    protein design, and by analyzing their roles in enabling patient-tailored interventions. It provides an integrated overview of the clinical applications of engineered therapeutic proteins across key medical fields, supported by a list of U.S. Food and Drug Administration- and European Medicines Agency-approved protein therapeutics from 2020 to 2025. The review further provides a comparative perspective on major protein engineering strategies, highlighting their relative advantages and limitations, while examining differences in clinical translation across major disease areas. By combining technological advances with disease-specific applications, this review offers a perspective that has not been fully developed in the literature. Finally, the review discusses the current challenges affecting the implementation of precision medicine, including immunogenicity, regulatory constraints, and ethical considerations, and outlines future directions, such as artificial intelligence-guided protein design, targeted protein degradation, and personalized vaccine development. Collectively, these insights highlight the expanding role of engineered proteins in shaping the next-generation of precision therapeutics and emphasize the growing importance of integrating multidisciplinary approaches to advance therapeutic innovation in modern clinical practice.\n                  <\/jats:p>","DOI":"10.3389\/fbioe.2026.1857362","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:49:55Z","timestamp":1791197395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances and applications of engineered protein therapeutics and their role in precision medicine"],"prefix":"10.3389","volume":"14","author":[{"given":"Wadha","family":"Aldossary","sequence":"first","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Asiri","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Alkhurayef","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Alagl","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Alturki","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duha","family":"Saad","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashael","family":"Al Yahya","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Al-Harthi","sequence":"additional","affiliation":[{"name":"Saudi Food and Drug Authority","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3906\/BIY-1411-8","article-title":"Development of therapeutic proteins: advances and challenges","volume":"39","author":"Akash","year":"2015","journal-title":"Turk. J. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11795549241298541","DOI":"10.1177\/11795549241298541","article-title":"Cancer biomarkers and precision oncology: a review of recent trends and innovations","volume":"18","author":"AlDoughaim","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"B4","unstructured":"Standards of care in diabetes to guide prevention, diagnosis, and treatment for people living with diabetes\n          \n          \n          2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/S13679-025-00623-1","article-title":"Dual and triple gut peptide agonists on the horizon for the treatment of type 2 diabetes and obesity. An overview of preclinical and clinical data","volume":"14","author":"Anastasiou","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41586-021-04184-w","article-title":"De novo protein design by deep network hallucination","volume":"600","author":"Anishchenko","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/J.ADDR.2021.01.019","article-title":"Overcoming barriers by local drug delivery with liposomes","volume":"174","author":"Antimisiaris","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1506767","DOI":"10.3389\/fphar.2024.1506767","article-title":"Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes","volume":"15","author":"Anwardeen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7384","DOI":"10.1002\/ALZ.14063","article-title":"Pathways to personalized medicine-embracing heterogeneity for progress in clinical therapeutics research in Alzheimer\u2019s disease","volume":"20","author":"Arnold","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B10","year":"2025","journal-title":"Transfus. Medicine History"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1439276","DOI":"10.3389\/fphar.2024.1439276","article-title":"Editorial: precision medicine: pecent advances, current challenges and future perspectives","volume":"15","author":"Awwad","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4161\/SELF.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"B13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/21655979.2015.1075674","article-title":"Genetically modified proteins: functional improvement and chimeragenesis","volume":"6","author":"Balabanova","year":"2015","journal-title":"Bioengineered"},{"key":"B14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/ANTIOX11020281","article-title":"Molecular mechanisms and therapeutic potential of \u03b1- and \u03b2-asarone in the treatment of neurological disorders","volume":"11","author":"Balakrishnan","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1200808","DOI":"10.3389\/fphar.2023.1200808","article-title":"Cell-based medicinal products approved in the European Union: current evidence and perspectives","volume":"14","author":"Bellino","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","article-title":"Strategies for extending the half-life of biotherapeutics: successes and complications","volume":"25","author":"Binder","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/BTT.S3103","article-title":"Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID)","volume":"3","author":"Booth","year":"2009","journal-title":"Biologics"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1089\/ipm.11.01.04","article-title":"The art of AI in drug discovery","author":"Branca","year":"2024","journal-title":"Inside Precis. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chembiol.2020.06.010","article-title":"Illuminating RNA biology: tools for imaging RNA in live mammalian cells","volume":"27","author":"Braselmann","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/FGENE.2018.00031","article-title":"Digital twins in health care: ethical implications of an emerging engineering paradigm","volume":"9","author":"Bruynseels","year":"2018","journal-title":"Front. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.4239\/WJD.V15.I8.1793","article-title":"Safety of teplizumab in patients with high risk for diabetes mellitus type 1: a systematic review","volume":"15","author":"Buddhavarapu","year":"2024","journal-title":"World J. Diabetes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","article-title":"Introduction to current and future protein therapeutics: a protein engineering perspective","volume":"317","author":"Carter","year":"2011","journal-title":"Exp. Cell Res."},{"key":"B25","article-title":"2019 antibiotic resistance threats report","year":"2025","journal-title":"Antimicrob. Resist."},{"key":"B26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/S10311-018-00841-1","article-title":"Nanocarriers for drug delivery applications","volume":"17","author":"Chamundeeswari","year":"2018","journal-title":"Environ. Chem. Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1529","DOI":"10.1002\/WCMS.1529","article-title":"Rational design of allosteric modulators: challenges and successes","volume":"11","author":"Chatzigoulas","year":"2021","journal-title":"WIREs Comput. Mol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41578-021-00399-5","article-title":"Integrating plant molecular farming and materials research for next-generation vaccines","volume":"7","author":"Chung","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"B29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.smaim.2020.04.001","article-title":"Nanoparticle-based drug delivery systems for cancer therapy","volume":"1","author":"Dang","year":"2020","journal-title":"Smart Mater. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"770102","DOI":"10.3389\/FCHEM.2021.770102","article-title":"Rational design of peptide-based smart hydrogels for therapeutic applications","volume":"9","author":"Das","year":"2021","journal-title":"Front. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/SCIENCE.ADD2187","article-title":"Robust deep learning\u2013based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.coph.2008.08.002","article-title":"Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates","volume":"8","author":"de Groot","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/molecules30030482","article-title":"The pharmaceutical industry in 2024: an analysis of the FDA drug approvals from the perspective of molecules","volume":"30","author":"de La Torre","year":"2025","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/JPM11111181","article-title":"Personalized medicine in autoimmune diseases","volume":"11","author":"D\u00edaz-Pe\u00f1a","year":"2021","journal-title":"J. Pers. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25163\/BIOSCIENCES.3120040","article-title":"Ethical considerations in the implementation of precision personalized medicine","volume":"3","author":"Dickens","year":"2021","journal-title":"J. Precis. Biosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1200\/JCO.2012.45.2268","article-title":"Genomic medicine frontier in human solid tumors: prospects and challenges","volume":"31","author":"Dienstmann","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","article-title":"Therapeutic proteins","volume":"899","author":"Dimitrov","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15857","DOI":"10.3390\/IJMS242115857","article-title":"Skin, autoimmunity and inflammation: a comprehensive exploration through scientific research","volume":"24","author":"Diotallevi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.medj.2025.100987","article-title":"Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis","volume":"7","author":"Dodd","year":"2026","journal-title":"Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1308296","DOI":"10.3389\/fneur.2024.1308296","article-title":"The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review","volume":"15","author":"Dosi","year":"2024","journal-title":"Front. Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/S41586-021-03899-0","article-title":"Rational design of a new antibiotic class for drug-resistant infections","volume":"597","author":"Durand-Reville","year":"2021","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17778","DOI":"10.1038\/s41598-023-45185-1","article-title":"Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes","volume":"13","author":"Ehsasatvatan","year":"2023","journal-title":"Sci. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2234787","DOI":"10.1080\/21645515.2023.2234787","article-title":"Restoring trust: the need for precision medicine in infectious diseases, public health and vaccines","volume":"19","author":"Equils","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/S41591-018-0316-Z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat. Med."},{"key":"B49","unstructured":"Alprolix"},{"key":"B50","unstructured":"Aranesp"},{"key":"B51","unstructured":"Hemgenix"},{"key":"B52","unstructured":"Lamzede"},{"key":"B53","unstructured":"MabThera"},{"key":"B54","year":"","journal-title":"Medicines"},{"key":"B55","unstructured":"Nplate"},{"key":"B56","unstructured":"Ogluo"},{"key":"B57","unstructured":"Pegasys"},{"key":"B58","unstructured":"Synagis"},{"key":"B204","unstructured":"Medicines"},{"key":"B59","unstructured":"Xevudy"},{"key":"B205","unstructured":"Rebif"},{"key":"B60","article-title":"Integrative AI-driven strategies for advancing precision medicine in infectious diseases and beyond: a novel multidisciplinary approach","author":"Fatima","year":"2023","journal-title":"Med. Adv. Innov. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/S40142-019-00177-4","article-title":"Opportunities for artificial intelligence in advancing precision medicine","volume":"7","author":"Filipp","year":"2019","journal-title":"Curr. Genet. Med. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1412006","DOI":"10.3389\/fnagi.2024.1412006","article-title":"Three major effects of APOE\u03b54 on A\u03b2 immunotherapy induced ARIA","volume":"16","author":"Foley","year":"2024","journal-title":"Front. Aging Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2450\/2019.0026-19","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus."},{"key":"B66","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1002\/MCO2.187","article-title":"Multifunctional nanoparticle for cancer therapy","volume":"4","author":"Gao","year":"2023","journal-title":"MedComm"},{"key":"B68","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1042\/EBC20200059","article-title":"Principles of synthetic biology","volume":"65","author":"Garner","year":"2021","journal-title":"Essays Biochem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B70","unstructured":"Genetic and rare diseases Information Centre (GARD)\n          \n          \n          2026"},{"key":"B71","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","article-title":"Precision medicine: from science to value","volume":"37","author":"Ginsburg","year":"2018","journal-title":"Health Aff. (Millwood)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/AJE\/KWAC063","article-title":"Aduhelm, the newly approved medication for Alzheimer disease: what epidemiologists can learn and what epidemiology can offer","volume":"191","author":"Glymour","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e4653","DOI":"10.1002\/PRO.4653","article-title":"De novo protein design by inversion of the AlphaFold structure prediction network","volume":"32","author":"Goverde","year":"2023","journal-title":"Protein Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1016\/J.XPHS.2020.09.025","article-title":"The confluence of innovation in therapeutics and regulation: recent CMC considerations","volume":"109","author":"Gutierrez","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/0333102413520084","article-title":"Calcitonin gene-related peptide and migraine with aura: a systematic review","volume":"34","author":"Hansen","year":"2014","journal-title":"Cephalalgia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/S41592-021-01090-X","article-title":"Directed evolution in mammalian cells","volume":"18","author":"Hendel","year":"2021","journal-title":"Nat. Methods."},{"key":"B78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod Alfa in generalised myasthenia gravis: a profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"B79","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40291-024-00696-z","article-title":"Exagamglogene autotemcel: first approval","volume":"28","author":"Hoy","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"B81","article-title":"Privacy must still come first","year":"2024","journal-title":"We\u2019re Call. Collaboration Developers As Report Reveals Future Innovations Data Protection Concerns Genomics"},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.37532\/2048-9145.2024.12(5).232-233","article-title":"Production of recombinant proteins: techniques, challenges, and future directions","volume":"12","author":"Izutsu","year":"2024","journal-title":"Pharm. Bioprocess."},{"key":"B83","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/17425247.2023.2200246","article-title":"Nanotechnology-enabled gene delivery for cancer and other genetic diseases","volume":"20","author":"Jiang","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"B84","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737159.2018.1428090","article-title":"When biomarkers define a drug indication","volume":"18","author":"J\u00f8rgensen","year":"2018","journal-title":"Expert Rev. Mol. diagn."},{"key":"B85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMRA1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4110\/IN.2022.22.E9","article-title":"Targeted immunotherapy for autoimmune disease","volume":"22","author":"Jung","year":"2022","journal-title":"Immune Netw."},{"key":"B87","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset pompe disease enrolled in the phase 2, open-label mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","article-title":"Clinical pharmacokinetics and use of infliximab","volume":"46","author":"Klotz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/NAR\/GKAD976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J. Biol. Eng."},{"key":"B92","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4161\/MABS.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"mAbs"},{"key":"B93","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/J.CELL.2023.12.028","article-title":"De novo protein design-From new structures to programmable functions","volume":"187","author":"Kortemme","year":"2024","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/ANNUREV-STATISTICS-030718-105251","article-title":"Precision medicine","volume":"6","author":"Kosorok","year":"2019","journal-title":"Annu. Rev. Stat. Its Appl."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e61983","DOI":"10.7759\/CUREUS.61983","article-title":"A comprehensive review of monoclonal antibodies in modern medicine: tracing the evolution of a revolutionary therapeutic approach","volume":"16","author":"Kothari","year":"2024","journal-title":"Cureus"},{"key":"B96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/NEJMoa1512693","article-title":"Proopiomelanocortin deficiency treated with a Melanocortin-4 receptor agonist","volume":"375","author":"K\u00fchnen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e202401055","DOI":"10.1002\/CBIC.202401055","article-title":"Directed evolution of fluorescent genetically encoded biosensors: innovative approaches for development and optimization of biosensors","volume":"26","author":"Kuldyushev","year":"2025","journal-title":"ChemBioChem"},{"key":"B98","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41591-019-0345-2","article-title":"Precision epidemiology for infectious disease control","volume":"25","author":"Ladner","year":"2019","journal-title":"Nat. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagass\u00e9","year":"2017","journal-title":"F1000Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"100122","DOI":"10.1016\/J.JTAUTO.2021.100122","article-title":"Ways in which the neonatal Fc-receptor is involved in autoimmunity","volume":"4","author":"Lamamy","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"B101","doi-asserted-by":"publisher","first-page":"104206","DOI":"10.1016\/J.DRUDIS.2024.104206","article-title":"Peptides as innovative strategies to combat drug resistance in cancer therapy","volume":"29","author":"Lamb","year":"2024","journal-title":"Drug Discov. Today."},{"key":"B102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/NRD2399","article-title":"Protein therapeutics: a summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"B103","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41467-023-35795-8","article-title":"Control of protein stability by post-translational modifications","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/PHARMACEUTICS15092233","article-title":"Recent advances in targeted drug delivery strategy for enhancing oncotherapy","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1353626","DOI":"10.3389\/fphar.2024.1353626","article-title":"Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"825312","DOI":"10.3389\/fimmu.2022.825312","article-title":"Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Immunol."},{"key":"B107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-12-824469-2.00013-0","article-title":"Advances in protein engineering and its application in synthetic biology","volume-title":"New Frontiers and Applications of Synthetic Biology","author":"Liu","year":"2022"},{"key":"B108","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1679092","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front. Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12929-025-01190-2","article-title":"Technological advancements in antibody-based therapeutics for treatment of diseases","volume":"32","author":"Lu","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/BLOOD-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"B113","article-title":"Understanding how monoclonal antibodies work","author":"Malik","year":"2023","journal-title":"StatPearls"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/S41390-025-04021-0","article-title":"Genomics and multiomics in the age of precision medicine","volume":"97","author":"Mani","year":"2025","journal-title":"Pediatr. Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tibtech.2018.11.002","article-title":"Synthetic biology tools to engineer microbial communities for biotechnology","volume":"37","author":"McCarty","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.trechm.2022.02.004","article-title":"High-throughput directed evolution: a golden era for protein science","volume":"4","author":"McLure","year":"2022","journal-title":"Trends Chem."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/med.21774","article-title":"Drug design targeting active posttranslational modification protein isoforms","volume":"41","author":"Meng","year":"2021","journal-title":"Med. Res. Rev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/FMED.2018.00067","article-title":"Precision medicine and global health: the good, the bad, and the ugly","volume":"5","author":"Mentis","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/BIOMEDICINES12122750","article-title":"Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives","volume":"12","author":"Molla","year":"2024","journal-title":"Biomedicines"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/IJMS26010002","article-title":"Cancer-targeting applications of cell-penetrating peptides","volume":"26","author":"Moreno-Vargas","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B121","volume-title":"Genetic Disorders","year":"2026"},{"key":"B122","unstructured":"Blood disorders and blood safety\n          \n          \n          2026"},{"key":"B123","first-page":"16","article-title":"A review on empirical approach to therapeutic recombinant protein production factories: applications, pharmacokinetics and challenges","volume":"9","author":"Naz","year":"2022","journal-title":"J. Bioresour. Manag."},{"key":"B124","doi-asserted-by":"publisher","first-page":"20220856","DOI":"10.1515\/BIOL-2022-0856","article-title":"New advances in protein engineering for industrial applications: key takeaways","volume":"19","author":"Ndochinwa","year":"2024","journal-title":"Open Life Sci."},{"key":"B125","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/S41587-024-02127-0","article-title":"Machine learning for functional protein design","volume":"42","author":"Notin","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/HEMATOLOGY.2023000518","article-title":"Barriers to accessing cellular therapy for patients receiving care in community practices","volume":"2023","author":"Nze","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"B127","doi-asserted-by":"publisher","first-page":"101136","DOI":"10.1016\/J.BLRE.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev."},{"key":"B128","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/J.JBC.2021.100558","article-title":"Recent advances in de novo protein design: principles, methods, and applications","volume":"296","author":"Pan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00390-6","article-title":"Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition","volume":"387","author":"Patel","year":"2016","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","article-title":"Gene therapy for neurological disorders: challenges and recent advancements","volume":"28","author":"Pena","year":"2020","journal-title":"J. Drug Target."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/JPS.22054","article-title":"Delivery of therapeutic proteins","volume":"99","author":"Pisal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-1826-4_9","article-title":"Rational-design engineering to improve enzyme thermostability","volume":"2397","author":"Pongsupasa","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12016-025-09054-1","article-title":"Effectiveness and safety of nemolizumab in patients with prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"Raja","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"e202200049","DOI":"10.1002\/CBIC.202200049","article-title":"Making enzymes suitable for organic chemistry by rational protein design","volume":"23","author":"Reetz","year":"2022","journal-title":"Chembiochem"},{"key":"B138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/9783527836895.ch1","article-title":"Introduction to directed evolution and rational design as protein engineering techniques","volume-title":"Enzyme Engineering: Selective Catalysts for Applications in Biotechnology, Organic Chemistry, and Life Science","author":"Reetz","year":"2023"},{"key":"B139","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJMoa2506549","article-title":"Stem cell\u2013derived, fully differentiated islets for type 1 diabetes","volume":"393","author":"Reichman","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40643-019-0288-Y","article-title":"Selection and screening strategies in directed evolution to improve protein stability","volume":"6","author":"Ren","year":"2019","journal-title":"Bioresour. Bioprocess."},{"key":"B141","volume-title":"Global Therapeutic Proteins Market Analysis Report 2022: A $100+ Billion Market in 2021\u2014Long-term Forecast to 2026 and 2031","year":"2022"},{"key":"B142","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B143","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1080\/08927022.2025.2562932","article-title":"Molecular dynamics simulations and structural bioinformatics of bacterial integral alpha-helical membrane enzymes and their AlphaFold2-predicted water-soluble QTY analogues","volume":"51","author":"Sajeev-Sheeja","year":"2025","journal-title":"Mol. Simul."},{"key":"B144","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.3390\/IJMS21176324","article-title":"Evolution of Escherichia coli expression system in producing antibody recombinant fragments","volume":"21","author":"Sandomenico","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1002\/AJH.26424","article-title":"Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia","volume":"97","author":"Santos","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B146","first-page":"395","volume-title":"Innovative Protein and Enzyme Engineering Processes for the Production of Biomass Hydrolyzing Enzymes","author":"Satapathy","year":"2022"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1210\/CLINEM\/DGZ310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B148","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-024-01788-1","article-title":"Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany","volume":"25","author":"Scheffler","year":"2024","journal-title":"J. Headache Pain"},{"key":"B149","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1039\/D2CB00231K","article-title":"A primer to directed evolution: current methodologies and future directions","volume":"4","author":"Sell\u00e9s Vidal","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1038\/S41467-024-54265-3","article-title":"Rational strategies for improving the efficiency of design and discovery of nanomedicines","volume":"15","author":"Shan","year":"2024","journal-title":"Nat. Commun."},{"key":"B152","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1200\/EDBK_359650","article-title":"Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective","volume":"42","author":"Shih","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1339714","DOI":"10.3389\/fimmu.2024.1339714","article-title":"Immune tolerance and the prevention of autoimmune diseases essentially depend on thymic tissue homeostasis","volume":"15","author":"Shirafkan","year":"2024","journal-title":"Front. Immunol."},{"key":"B155","unstructured":"25 transformative years of biosimilars. BioSpectrum India\n          \n          \n            \n              Siddiqui\n              A.\n            \n          \n          \n          2025"},{"key":"B156","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3390\/ANTIB8020036","article-title":"Current advancements in addressing key challenges of therapeutic antibody design, manufacture, and formulation","volume":"8","author":"Sifniotis","year":"2019","journal-title":"Antibodies"},{"key":"B157","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1007\/s12325-023-02689-6","article-title":"Long-term outcomes of eladocagene exuparvovec compared with standard of care in aromatic L-amino acid decarboxylase (AADC) deficiency: a modelling study","volume":"40","author":"Simons","year":"2023","journal-title":"Adv. Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/NAR\/GKZ954","article-title":"Evolution-guided engineering of small-molecule biosensors","volume":"48","author":"Snoek","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B161","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Tan","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"B162","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/S13045-023-01482-W","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/JMDH.S313968","article-title":"Targeted drug delivery \u2014 from magic bullet to nanomedicine: principles, challenges, and future perspectives","volume":"14","author":"Tewabe","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"B164","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B165","unstructured":"Global HIV and AIDS statistics\u2014Fact sheet\n          \n          \n          2026"},{"key":"B166","unstructured":"Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19\n          \n          \n          2020"},{"key":"B167","unstructured":"FDA approves first cellular therapy to treat patients with type 1 diabetes"},{"key":"B168","unstructured":"FDA approves first gene therapies to treat patients with sickle cell disease"},{"key":"B169","unstructured":"100 years of insulin"},{"key":"B170","unstructured":"ABECMA"},{"key":"B171","unstructured":"Approved cellular and gene therapy products"},{"key":"B172","unstructured":"FDA approves dostarlimab-gxly with Chemotherapy for Endometrial Cancer"},{"key":"B173","unstructured":"FDA approves mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer"},{"key":"B174","unstructured":"FDA approves Opdualag for unresectable or metastatic melanoma"},{"key":"B175","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma"},{"key":"B176","unstructured":"Notable approvals"},{"key":"B178","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-018-0098-9","article-title":"Developmental roadmap for antimicrobial susceptibility testing systems","volume":"17","author":"van Belkum","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1039\/D1CC04635G","article-title":"High-throughput screening, next generation sequencing and machine learning: advanced methods in enzyme engineering","volume":"58","author":"Vanella","year":"2022","journal-title":"Chem. Commun. (Camb)"},{"key":"B181","doi-asserted-by":"publisher","first-page":"114142","DOI":"10.1016\/j.addr.2022.114142","article-title":"Toward rational vaccine engineering","volume":"183","author":"Vishweshwaraiah","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B182","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: \u201csuper-antibodies\u201d enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/NRC.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"B184","doi-asserted-by":"publisher","first-page":"e16716","DOI":"10.1002\/aic.16716","article-title":"Biosystems design by directed evolution","volume":"66","author":"Wang","year":"2020","journal-title":"AIChE J."},{"key":"B185","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/J.ORET.2020.10.004","article-title":"Dose-response relationship between intravitreal injections and retinal nerve fiber layer thinning in age-related macular degeneration","volume":"5","author":"Wang","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"B186","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"682675","DOI":"10.3389\/fchem.2021.682675","article-title":"Rational design of peptide-based inhibitors disrupting protein-protein interactions","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Chem."},{"key":"B188","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1021\/ACS.CHEMREV.1C00260","article-title":"Directed evolution: methodologies and applications","volume":"121","author":"Wang","year":"2021","journal-title":"Chem. Rev."},{"key":"B189","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/diagnostics13122037","article-title":"A systematic database approach to identify companion diagnostic testing in clinical trials under the new in vitro diagnostic medical devices regulation","volume":"13","author":"Wollenhaupt","year":"2023","journal-title":"Diagn. (Basel)"},{"key":"B191","unstructured":"Ebola disease\n          \n          \n          2025"},{"key":"B192","unstructured":"COVID-19 cases | WHO COVID-19 dashboard. WHO data"},{"key":"B193","volume-title":"Infectious Diseases","year":""},{"key":"B194","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12933-025-02696-7","article-title":"Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"24","author":"Wu","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"B195","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13073-021-00896-w","article-title":"Translating the human microbiome: a path to improving health","volume":"13","author":"Xavier","year":"2021","journal-title":"Genome Med."},{"key":"B196","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/B978-0-444-64085-7.00009-5","article-title":"Biosynthetic technology and bioprocess engineering","volume-title":"Current Developments in Biotechnology and Bioengineering","author":"Xin","year":"2019"},{"key":"B197","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.3390\/IJMS25147666","article-title":"Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies","volume":"25","author":"Yasmeen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B198","doi-asserted-by":"publisher","first-page":"570280","DOI":"10.3389\/FMICB.2020.570280","article-title":"Random mutagenesis by insertion of error-prone PCR products to the chromosome of Bacillus subtilis","volume":"11","author":"Ye","year":"2020","journal-title":"Front. Microbiol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u2265 4 to < 8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (Endeavor)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Control. Release."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.ymthe.2022.02.018","article-title":"Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."},{"key":"B202","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/S12896-021-00693-8","article-title":"Rational design and structure-based engineering of alkaline pectate lyase from Paenibacillus sp. 0602 to improve thermostability","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Biotechnol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41390-019-0611-5","article-title":"Genotype\u2013phenotype analysis of 523 patients by genetics evaluation and clinical exome sequencing","volume":"87","author":"Ziats","year":"2020","journal-title":"Pediatr. Res."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1857362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:50:03Z","timestamp":1791197403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1857362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":203,"alternative-id":["10.3389\/fbioe.2026.1857362"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1857362","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1857362"}}